28,895 Shares in Twist Bioscience Corporation $TWST Acquired by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the 3rd quarter, HoldingsChannel reports. The fund purchased 28,895 shares of the company’s stock, valued at approximately $5,584,000. Twist Bioscience accounts for 1.5% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 20th largest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Western Wealth Management LLC acquired a new stake in shares of Twist Bioscience during the 1st quarter valued at $31,000. Root Financial Partners LLC acquired a new stake in shares of Twist Bioscience in the third quarter worth $33,000. PNC Financial Services Group Inc. boosted its position in Twist Bioscience by 89.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock worth $46,000 after acquiring an additional 453 shares during the period. Fifth Third Bancorp purchased a new position in Twist Bioscience during the first quarter valued at approximately $54,000. Finally, Allworth Financial LP purchased a new position in shares of Twist Bioscience during the 2nd quarter valued at $62,000.

Analyst Ratings Changes

A number of equities analysts recently commented on TWST shares. Guggenheim increased their price objective on Twist Bioscience from $107.00 to $212.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. UBS Group assumed coverage on Twist Bioscience in a research note on Wednesday, September 9th. They set a “neutral” rating and a $144.00 target price for the company. Jefferies Financial Group began coverage on shares of Twist Bioscience in a report on Thursday, October 8th. They set a “hold” rating and a $150.00 price objective on the stock. Robert W. Baird raised their target price on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Finally, TD Cowen lifted their price objective on Twist Bioscience from $115.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Seven analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Twist Bioscience has a consensus rating of “Hold” and an average target price of $153.00.

Insider Buying and Selling

In related news, CFO Adam Laponis sold 2,462 shares of the stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $156.30, for a total transaction of $384,810.60. Following the completion of the sale, the chief financial officer owned 98,114 shares in the company, valued at $15,335,218.20. This trade represents a 2.45% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 949 shares of Twist Bioscience stock in a transaction dated Tuesday, November 3rd. The shares were sold at an average price of $135.40, for a total transaction of $128,494.60. Following the transaction, the insider directly owned 62,840 shares of the company’s stock, valued at $8,508,536. This represents a 1.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 495,279 shares of company stock worth $80,489,387 in the last three months. Company insiders own 3.08% of the company’s stock.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $122.59 on Thursday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. The stock has a fifty day moving average price of $150.90 and a two-hundred day moving average price of $92.37. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The firm has a market capitalization of $7.69 billion, a P/E ratio of -55.22 and a beta of 2.25.

About Twist Bioscience

Twist Bioscience Corporation is a biotechnology company that uses a silicon-based platform to manufacture synthetic DNA. Its technology supports the production of many DNA sequences in parallel for research and commercial applications. The company provides synthetic genes, gene fragments and oligonucleotide pools, as well as tools for next-generation sequencing, including target-enrichment products. Through its biopharma business, Twist also offers antibody discovery and related services to support the development of therapeutics.